BioCentury
ARTICLE | Financial News

Vivace out of stealth with $40M in two rounds

June 28, 2017 1:24 PM UTC

Cancer play Vivace Therapeutics Inc. (San Mateo, Calif.) emerged from stealth mode and announced a $25 million series B round led by new investor Cenova Capital. Also participating were new investor Sequoia Capital China and existing investors Canaan Partners, WuXi Healthcare Ventures and Mission Bay Capital. Canaan and WuXi co-led Vivace's $15 million series A round in 2015, also announced Wednesday.

Vivace is developing two programs in parallel. The first focuses on the Hippo-YAP signaling pathway, where Vivace is developing inhibitors of LATS large tumor suppressor homolog 1 (LATS1) and LATS2 to treat cancer. The company is also developing activators of the Hippo-YAP pathway for immuno-oncology applications. Vivace declined to disclose a timeline for entering the clinic...